New trends in photobiology: The role of the low density lipoprotein receptor pathway in the delivery of lipophilic photosensitizers in the photodynamic therapy of tumours

doi:10.1016/1011-1344(91)80111-T

Journal of Photochemistry and Photobiology B: Biology

Volume 8, Issue 4, March 1991, Pages 351-360

https://doi.org/10.1016/1011-1344(91)80111-T Get rights and content

Abstract

Lipoproteins are now recognized as major blood carriers of many hydrophobic porphyrins and related chromophores which are being investigated as possible photosensitizers in the photodynamic therapy of tumours. In vitro and in vivo studies have demonstrated the role of the low density lipoprotein (LDL) receptor pathway in the delivery of photosensitizers to tumour cells and its importance in porphyrin accumulation by tumours. Lysosomes, which are involved in the cellular processing of LDL, are important intracellular targets in the LDL—porphyrin-induced phototoxicity. The use of the LDL receptor pathway as a tool for enhancing the selectivity of photosensitizer delivery to tumour cells appears to be a promising field of research in the photodynamic therapy of tumours.

References (46)

I. Diamond et al.
Photodynamic therapy of malignant tumors
The Lancet
(1972)
G. Jori et al.
Evidence for a major role of plasma lipoproteins as hematoporphyrin carriers in vivo
Cancer Lett.
(1984)
J.C. Mazière et al.
Cholesterol metabolism in normal and SV40 transformed hamster fibroblasts, Effect of LDL
Biochimie
(1981)
C. Candide et al.
In vitro interaction of the photoactive anticancer porphyrin derivative photofrin II with low density lipoprotein, and its delivery to cultured human fibroblasts
FEBS Lett.
(1986)
D. Kessel
Porphyrin—lipoprotein association as a factor in porphyrin localization
Cancer Lett.
(1986)
M.J. Chapman
Animal lipoproteins: Chemistry, structure and comparative aspects
J. Lipid Res.
(1980)
A. Barel et al.
Role of high-, low- and very low density lipoproteins in the transport and tumour-delivery of hematoporphyrin in vivo
Cancer Lett.
(1986)
C. Candide et al.
Photosensitization of Wi26-VA4 transformed human fibroblasts by low density lipoproteins loaded with the anticancer porphyrin derivative photofrin II: evidence for endoplasmic reticulum alteration
Cancer Lett.
(1989)
P. Morlière et al.
Synthesis, cellular uptake of, and cell photosensitization by a porphyrin bearing a quinoline group
J. Photochem. Photobiol. B: Biol.
(1990)
J.C. Mazière et al.
Cellular uptake and photosensitizing properties of anticancer porphyrins in cell membranes and low and high density lipoproteins
J. Photochem. Photobiol. B: Biol.
(1990)

D.W. Morel et al.

Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid

J. Lipid Res.

(1983)

S.A. Evensen et al.

LDL-induced cytotoxicity and its inhibition by anti-oxidant treatment in cultured endothelial cells and fibroblasts

Atherosclerosis

(1983)

P.J. Bugelski et al.

Auto-radiographic distribution of hematoporphyrin derivative in normal and tumour tissue of the mouse

Cancer Res.

(1981)

A.A. Lamola

Fluorescence studies of protoporphyrin transport and clearance

Acta Derm-Venereol. Suppl.

(1982)

J.P. Reyftmann et al.

Interaction of human serum low density lipoproteins with porphyrins: a spectroscopic and photochemical study

Photochem. Photobiol.

(1984)

G. Jori

In vivo transport and pharmacokinetic behaviour of tumour photosensitizers

J. Moan et al.

Binding of porphyrins to serum proteins

Adv. Exp. Med. Biol.

(1985)

Y.K. Ho et al.

Low density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells

Blood

(1979)

D. Gal et al.

Cholesterol metabolism in cancer cells in monolayer culture. III. Low density lipoprotein metabolism

Int. J. Cancer

(1981)

M. Beltramini et al.

Steady-state and time-resolved spectroscopic studies on the hematoporphyrin—lipoprotein complex

Biochemistry

(1987)

M. Kongshaug et al.

The distribution of porphyrins with different tumour localising ability among human plasma proteins

Br. J. Cancer.

(1989)

C. Candide et al.

Modification of epsilon-amino group of lysines, cholesterol oxidation and oxidized lipid—apoprotein cross-link formation by porphyrin-photosensitized oxidation of human low density lipoproteins

Photochem. Photobiol.

(1988)

D. Kessel

In vitro photosensitization with a benzoporphyrin derivative

Photochem. Photobiol.

(1989)

Cited by (164)

Targeted strategies to deliver boron agents across the blood–brain barrier for neutron capture therapy of brain tumors
2024, International Journal of Pharmaceutics
Boron neutron capture therapy (BNCT), as an innovative radiotherapy technology, has demonstrated remarkable outcomes when compared to conventional treatments in the management of recurrent and refractory brain tumors. However, in BNCT of brain tumors, the blood–brain barrier is a main stumbling block for restricting the transport of boron drugs to brain tumors, while the tumor targeting and retention of boron drugs also affect the BNCT effect. This review focuses on the recent development of strategies for delivering boron drugs crossing the blood–brain barrier and targeting brain tumors, providing new insights for the development of efficient boron drugs for the treatment of brain tumors.
Hypericin supramolecular assembles: A way to increase the skin availability and photodynamic efficiency in tumor cells
2023, Photodiagnosis and Photodynamic Therapy
Cyclodextrins (CDs) are molecules approved by the FDA and show promise in increasing the solubility of hydrophobic molecules and making them more available to the skin. These CDs have been used to form complexes with some photosensitizers for Photodynamic Therapy (PDT), such as Hypericin (HY). HY is a lipophilic photosensitizer known for its exceptional fluorescence and singlet oxygen quantum yield generation of over 20 % under 590 nm irradiation. In this study, we found a six-fold increase in the release of HY in vitro after complexation with β-CD. The β-CDHY assembly also demonstrated better skin retention, which is crucial for the topical application of this photosensitizer. Furthermore, the β-CD complexation led to a significant increase in the phototoxicity of HY at three different light doses (3, 6, and 10 J cm⁻²) due to its improved water solubility and higher in vitro accumulation (approximately two times compared with free HY) in HeLa and Vero cell lines.
Low-density lipoprotein: a versatile nanoscale platform for targeted delivery
2023, Nanoscale Advances
Low-density lipoprotein (LDL) is a small lipoprotein that plays a vital role in controlling lipid metabolism. LDL has a delicate nanostructure with unique physicochemical properties: superior payload capacity, long residence time in circulation, excellent biocompatibility, smaller size, and natural targeting. In recent decades, the superiority and feasibility of LDL particles as targeted delivery carriers have attracted much attention. In this review, we introduce the structure, composition, advantages, defects, and reconstruction of LDL delivery systems, summarize their research status and progress in targeted diagnosis and therapy, and finally look forward to the clinical application of LDL as an effective delivery vehicle.
Blood distribution and plasma protein binding of PHOTOCYANINE: a promising phthalocyanine photosensitizer inphaseⅡ clinical trials
2020, European Journal of Pharmaceutical Sciences
Citation Excerpt :
Therefore, in comparison with AAG, HSA may play a predominant role in carrying and transporting PHOTOCYANINE to the tumor tissues. It was reported that the association of photosensitizers with lipoproteins promotes their selective accumulation into tumor tissues, and then enhances the PDT anticancer activity (Maziere et al., 1991). Therefore, the distribution of PHOTOCYANINE in lipoproteins fractions, such as very low-density lipoproteins (VLDL), low-density lipoproteins (LDL) and high-density lipoproteins (HDL), was investigated by the density gradient ultracentrifugation and the concentration of PHOTOCYANINE in the lipoprotein fractions was measured by the fluorescence method.
Blood distribution and plasma protein binding are the important properties that can influence pharmacokinetics and ultimately the anticancer efficacy of photosensitizers in clinical photodynamic therapy. As a novel and promising phthalocyanine photosensitizer under clinical phase Ⅱ investigation in China, the superiority of PHOCYANINE is speculated on its attribution to its binding with plasma proteins. To verify this hypothesis, explore the targeting mechanism and further apply foundation for its clinical trial evaluation, we further study its in vitro and in vivo human blood distribution, in vitro plasma protein and lipoprotein binding in detail. PHOTOCYANINE was found to be mainly distributed in plasma with low K_BP and K_EP values. Moreover, its high binding rates to plasma proteins among various species (mouse, rat, dog, monkey, and human) were then determined. Among these plasma proteins, human serum albumin and α1-acid-glycoprotein were found to bind PHOTOCYANINE highly, and low-density lipoproteins have the highest percentage of PHOTOCYANINE over other lipoproteins. This study is expected to provide some guidance for PDT clinical evaluations and for further molecular design and development of photosensitizers.
Upconversion luminescence mediated photodynamic therapy through hydrophilically engineered porphyrin
2019, Chemical Engineering and Processing - Process Intensification
Citation Excerpt :
Furthermore, it was found out that the UCNP-PJ probes irradiated under 980 nm laser exhibit comparable efficiency in generation of cytotoxic ROS in comparison with that of the clinically used HMME excited at 635 nm with the same irradiation density. The UCNP-PJ probes are expected to possess tumor targeting ability, as porphyrins can be captured by low density lipoprotein (LDL) receptors on the surfaces of cancer cells and enter the cells through receptor-mediated endocytosis [50]. Therefore, the specific binding assay was performed using LS180 cells which highly express LDL receptors on their surfaces.
Photodynamic therapy that involves the photosensitizer transferring the absorbed energy to surrounding tissue oxygen has been used in clinical treatment of cancer. However, the clinically used porphyrin derivatives as PDT photosensitizers usually need high energy excitation light, which generally gives rise to limited tissue penetration depth and thereby limited photoactivation efficiency. Herein, protoporphyrin IX was chemically modified by jeffamines for improving the hydrophilicity and biocompatibility, and the resulting water-soluble porphyrin-jeffamine (PJ) was further covalently conjugated to the PEGylated upconversion nanoparticles (UCNPs) via “click” reaction, which is an efficient way to precisely control the resonance energy transfer from UCNPs to PJs. Our work demonstrates that, the probes can be effectively photosensitized to produce reactive oxygen species (ROS) under the excitation of 980 nm NIR light. When compared with the clinically used photosensitizer molecules, the probes exhibit a comparable capability for producing ROS. Besides, the probes present an outstanding ability in targeting tumor cells and high efficiency in inducing cell death through the photoactivation by 980 nm laser.
Photodynamic therapy – mechanisms, photosensitizers and combinations
2018, Biomedicine and Pharmacotherapy
Citation Excerpt :
Lipoproteins play an important role in the transport and release of photosensitizer molecules to cancer cells. Several studies show that a photosensitizer bonded non-covalently to LDL prior to administration leads to an increase in PDT efficiency compared to the administration of the photosensitizer itself (Scheme 3) [63,69,70]. Electroporation (EP) is a technique of reversible or irreversible cell membrane unsealing induced by electrical pulses.
Photodynamic therapy (PDT) is a modern and non-invasive form of therapy, used in the treatment of non-oncological diseases as well as cancers of various types and locations. It is based on the local or systemic application of a photosensitive compound - the photosensitizer, which is accumulated in pathological tissues. The photosensitizer molecules absorb the light of the appropriate wavelength, initiating the activation processes leading to the selective destruction of the inappropriate cells. The photocytotoxic reactions occur only within the pathological tissues, in the area of photosensitizer distribution, enabling selective destruction. Over the last decade, a significant acceleration in the development of nanotechnology has been observed. The combination of photosensitizers with nanomaterials can improve the photodynamic therapy efficiency and eliminate its side effects as well. The use of nanoparticles enables achievement a targeted method which is focused on specific receptors, and, as a result, increases the selectivity of the photodynamic therapy. The object of this review is the anticancer application of PDT, its advantages and possible modifications to potentiate its effects.

View all citing articles on Scopus

View full text

Invited reviewNew trends in photobiology: The role of the low density lipoprotein receptor pathway in the delivery of lipophilic photosensitizers in the photodynamic therapy of tumours

Abstract

The Lancet

Cancer Lett.

Biochimie

FEBS Lett.

Cancer Lett.

J. Lipid Res.

Cancer Lett.

Cancer Lett.

J. Photochem. Photobiol. B: Biol.

J. Photochem. Photobiol. B: Biol.

J. Lipid Res.

Atherosclerosis

Auto-radiographic distribution of hematoporphyrin derivative in normal and tumour tissue of the mouse

Cancer Res.

Fluorescence studies of protoporphyrin transport and clearance

Acta Derm-Venereol. Suppl.

Interaction of human serum low density lipoproteins with porphyrins: a spectroscopic and photochemical study

Photochem. Photobiol.

In vivo transport and pharmacokinetic behaviour of tumour photosensitizers

Binding of porphyrins to serum proteins

Adv. Exp. Med. Biol.

Low density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells

Blood

Cholesterol metabolism in cancer cells in monolayer culture. III. Low density lipoprotein metabolism

Int. J. Cancer

Steady-state and time-resolved spectroscopic studies on the hematoporphyrin—lipoprotein complex

Biochemistry

The distribution of porphyrins with different tumour localising ability among human plasma proteins

Br. J. Cancer.

Modification of epsilon-amino group of lysines, cholesterol oxidation and oxidized lipid—apoprotein cross-link formation by porphyrin-photosensitized oxidation of human low density lipoproteins

Photochem. Photobiol.

In vitro photosensitization with a benzoporphyrin derivative

Photochem. Photobiol.

Invited review
New trends in photobiology: The role of the low density lipoprotein receptor pathway in the delivery of lipophilic photosensitizers in the photodynamic therapy of tumours